Abstract |
T-3811, the free base of T-3811ME (BMS-284756), a new des-F(6)-quinolone, showed a potent in vitro activity (MIC at which 90% of the isolates tested are inhibited [MIC(90)], 0.0313 microg/ml) against Mycoplasma pneumoniae. The MIC(90) of T-3811 was 4-fold higher than that of clarithromycin but was 4- to 8-fold lower than those of trovafloxacin, gatifloxacin, gemifloxacin, and moxifloxacin and was 16- to 32-fold lower than those of levofloxacin, ciprofloxacin, and minocycline. In an experimental M. pneumoniae pneumonia model in hamsters, after the administration of T-3811ME (20 mg/kg of body weight as T-3811, once daily, orally) for 5 days, the reduction of viable cells of M. pneumoniae in bronchoalveolar lavage fluid was greater than those of trovafloxacin, levofloxacin, and clarithromycin (20 and 40 mg/kg, orally) (P < 0.05).
|
Authors | M Takahata, M Shimakura, R Hori, K Kizawa, Y Todo, S Minami, Y Watanabe, H Narita |
Journal | Antimicrobial agents and chemotherapy
(Antimicrob Agents Chemother)
Vol. 45
Issue 1
Pg. 312-5
(Jan 2001)
ISSN: 0066-4804 [Print] United States |
PMID | 11120986
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Infective Agents
- Fluoroquinolones
- Indoles
- Isoindoles
- Quinolones
- T 3811ME
|
Topics |
- Animals
- Anti-Infective Agents
(pharmacology, therapeutic use)
- Bronchoalveolar Lavage Fluid
(microbiology)
- Cricetinae
- Fluoroquinolones
- Indoles
(pharmacology, therapeutic use)
- Isoindoles
- Lung
(microbiology)
- Male
- Mesocricetus
- Microbial Sensitivity Tests
- Mycoplasma pneumoniae
(drug effects)
- Pneumonia, Mycoplasma
(drug therapy, microbiology)
- Quinolones
(pharmacology, therapeutic use)
|